8-K: ATAI Files Pro Forma for Beckley Psytech Acquisition

ATAI Life Sciences N.V. filed pro forma financial information and Beckley Psytech's audited financials in connection with its planned acquisition, expected to close in Q4 2025.

Summary

• ATAI Life Sciences N.V. is proceeding with the acquisition of Beckley Psytech Limited, a company in which ATAI already holds a 33.7% investment.
• The acquisition is expected to close in the fourth quarter of 2025, subject to ATAI shareholder approval and other customary closing conditions.
• Prior to closing, Beckley Psytech will spin off Eleusis and its subsidiaries to its existing shareholders, with ATAI retaining a 33.7% interest in Eleusis.
• Beckley Psytech reported significant net losses: £22.469 million in 2024, £6.002 million in 2023, and £30.193 million in 2022.
• Beckley Psytech had cash and cash equivalents of £5.082 million as of December 31, 2024, and has a material uncertainty regarding its ability to continue as a going concern without additional funding.
• ATAI provided a senior promissory note of up to $10.0 million (approximately £7.4 million) to Beckley Psytech to fund BPL-003 development milestones.
• ATAI completed a July PIPE Financing, raising approximately $50.0 million through the issuance of 18,264,840 Ordinary Shares and pre-funded warrants for 4,566,210 Ordinary Shares.
• Unaudited pro forma condensed combined financial information for ATAI, giving effect to the acquisition and related transactions, shows a net loss of $(85.625) million for the six months ended June 30, 2025, and $(721.186) million for the year ended December 31, 2024.
• The estimated preliminary purchase consideration for the acquisition is approximately $523.2 million, based on the RSU Consideration Scenario.
• ATAI plans a Redomiciliation to Luxembourg and then Delaware, expected to be completed before the end of 2025, with estimated transaction costs of approximately $3.0 million.

Sentiment

Score: 8

Explanation: The positive topline results for BPL-003-201 Phase 2b study represent a significant de-risking event and a major positive for ATAI's pipeline. The strategic acquisition of Beckley Psytech, integrating this promising asset, strengthens ATAI's market position in psychedelic medicine. While Beckley Psytech's historical financials show losses, this is typical for a pre-revenue biotech, and the acquisition provides necessary funding and stability.

Positives

• Topline results of the BPL-003-201 Phase 2b study announced on July 1, 2025, met its primary and all key secondary endpoints, demonstrating rapid, robust, and durable antidepressant effects with a single dose.
• ATAI is strategically acquiring Beckley Psytech, integrating a promising clinical-stage asset (BPL-003) into its pipeline.
• ATAI provided a $10.0 million promissory note to Beckley Psytech, ensuring funding for BPL-003 development milestones.
• The July PIPE Financing raised $50.0 million, strengthening ATAI's capital position.

Negatives

• Beckley Psytech has incurred significant net losses and net cash outflows from operating activities since inception, with a net loss of £22.469 million in 2024.
• Beckley Psytech's financial statements include a material uncertainty related to its ability to continue as a going concern without additional financing.
• The pro forma combined entity (ATAI and Beckley Psytech) is expected to continue incurring significant losses, with a pro forma net loss of $(721.186) million for the year ended December 31, 2024.
• Goodwill of £13.9 million recognized in the 2022 acquisition of Eleusis was fully impaired due to the estimated value in use being less than its carrying value.

Risks

• The acquisition of Beckley Psytech may not be completed in a timely manner or at all, including the risk that required shareholder approvals are not obtained.
• Failure to realize the anticipated benefits of the proposed transactions.
• The possibility that any or all of the various conditions to the consummation of the proposed transactions may not be satisfied or waived.
• The occurrence of any event, change, or other circumstance that could give rise to the termination of the Share Purchase Agreement.
• The effect of the announcement or pendency of the proposed transactions on ATAI's ability to retain and hire key personnel, or its operating results and business generally.
• Beckley Psytech's ability to continue as a going concern is uncertain without additional funding, which could impact its financial condition and ability to pursue business strategies.
• There is no guarantee that ATAI will provide adequate cash inflows to Beckley Psytech following the closing of the transaction, nor that other additional funding or R&D tax credits will be received in time.
• The final purchase price allocation for the acquisition may differ materially from preliminary estimates due to changes in ATAI's common stock fair value, timing of closing, and changes in Beckley Psytech's assets and liabilities.

Future Outlook

The acquisition of Beckley Psytech is expected to close in the fourth quarter of 2025, subject to shareholder approval. ATAI also plans to complete a Redomiciliation to Luxembourg and then Delaware before the end of 2025. Beckley Psytech expects to continue to be eligible for the enhanced R&D intensive support scheme (ERIS) for tax credits. The Eleusis cash-generating unit (CGU) is not expected to reach commercialization until 2031.

Management Comments

• Management believes its judgments, assumptions, and estimates are appropriate, though actual results may differ materially from such estimates under different assumptions, macroeconomic, and market conditions.
• Management has prepared the consolidated financial statements on a going concern basis due to the expectation that the acquisition will conclude, additional cash inflows will be provided by ATAI, and R&D tax credits will be received.

Industry Context

This announcement is significant for the psychedelic medicine industry, as it consolidates a key clinical-stage asset (BPL-003) under ATAI, a prominent player in the sector. The positive Phase 2b results for BPL-003 could accelerate its development and potential market entry, contributing to the growing acceptance and therapeutic application of psychedelic compounds for mental health conditions.

Related Party Transactions

• ATAI Life Sciences N.V. holds a 33.7% investment in Beckley Psytech Limited.
• ATAI provided a senior promissory note of up to $10.0 million to Beckley Psytech.
• Payments of £0.03 million were made to the Beckley Foundation from Beckley Psytech in 2024 (and prior years) in relation to a payment license, with a commitment to pay a 1% royalty of net revenues once revenue-generating.

Stakeholder Impact

• Shareholders of ATAI will vote on the acquisition and will experience dilution from the issuance of new shares for the acquisition and the July PIPE Financing, but gain a promising clinical asset.
• Existing shareholders of Beckley Psytech will receive ATAI shares as consideration for the acquisition and a pro-rata equity holding in Eleusis.
• Beckley Psytech optionholders will have their options replaced with ATAI awards or consideration shares, subject to vesting and in-the-money status.
• Employees of Beckley Psytech will become part of the combined ATAI organization, with their share options being replaced.
• Future patients could benefit from the accelerated development and potential commercialization of BPL-003 for antidepressant effects.

Next Steps

• ATAI shareholders to vote on the acquisition of Beckley Psytech.
• Closing of the acquisition of Beckley Psytech, expected in Q4 2025.
• Beckley Psytech to spin off Eleusis and its subsidiaries to existing shareholders prior to closing.
• ATAI to complete its Redomiciliation to Luxembourg and then Delaware before the end of 2025.
• Continued development of BPL-003 following positive Phase 2b results.

Key Dates

Recommendation

The positive topline results from the BPL-003-201 Phase 2b study are a significant catalyst, demonstrating strong efficacy and de-risking a key asset in ATAI's pipeline. The strategic acquisition of Beckley Psytech, with this promising compound, consolidates ATAI's position in the growing psychedelic medicine market. While Beckley Psytech's historical financials show losses, this is typical for a pre-revenue biotech, and the acquisition provides necessary funding and a clear path forward for BPL-003. The July PIPE financing also strengthens ATAI's balance sheet. These developments collectively present a compelling investment opportunity for long-term growth in a high-potential therapeutic area.

Keywords

ATAI Life Sciences, Beckley Psytech, Acquisition, SEC Filing, 8-K, BPL-003, Clinical Trials, Phase 2b, Psychedelic Medicine, Financial Statements, Pro Forma, Going Concern, PIPE Financing, Redomiciliation, Eleusis